Antiplatelet Strategy for Peripheral Arterial Interventions for Revascularization of Lower Extremities
Information source: University of Texas Southwestern Medical Center
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Peripheral Arterial Disease
Intervention: Endovascular revascularization (Procedure); 1 month daily 75 mg plavix (Drug); 12 months daily 75 mg plavix (Drug); 12 months daily 75-100 mg aspirin (Drug); 1 month daily 75-100 mg aspirin (Drug)
Phase: Phase 3
Status: Not yet recruiting
Sponsored by: University of Texas Southwestern Medical Center Official(s) and/or principal investigator(s): Subhash Banerjee, MD, Study Chair, Affiliation: University of Texas Southwestern Medical Center
Overall contact: Atif Mohammad, MD, Phone: 2147428387, Ext: 76630, Email: Atif.Mohammad@utsouthwestern.edu
Summary
The purpose of this study is to evaluate whether clopidogrel 75 mg daily on a background of
aspirin 75-100 mg/d for 12 months or for 1 months will lead to an increased rate of primary
patency, limb salvage, non-fatal myocardial infarction (MI), ischemic stroke, and survival,
in patients receiving endovascular treatment of PAD at 1 year.
Clinical Details
Official title: Antiplatelet Strategy for Peripheral Arterial Interventions for Revascularization of Lower Extremities
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Target vessel occlusionSurgical revascularization Endovascular revascularization Major amputation of the target limb Ischemic Stroke Myocardial infarction Death
Secondary outcome: Bleeding
Detailed description:
Peripheral arterial disease (PAD) is extremely prevalent worldwide and affects over 206
million people. Over 36 million patients with PAD are estimated to be present in the United
States. Percutaneous revascularization therapies have evolved dramatically, yet the
long-term success of these therapies remains modest and the morbidity and mortality
associated with PAD remains high, with up to 30% mortality risk at 5 years. Nearly, 3. 2
million endovascular procedures are performed annually. Though, this exceeds interventional
procedures performed for coronary artery disease (CAD), the current PAD guidelines are
silent regarding the need and optimal duration of antiplatelet therapy (APT) for patients
following an endovascular procedure for claudication or critical limb ischemia (CLI). The
lack of data and clinical studies is by far the greatest impediment to the formulation of
such guideline recommendations critically needed by providers and patients alike, especially
given the current limited durability of lower extremity endovascular procedures.
The objective of this trial is to evaluate whether clopidogrel 75 mg QD on a background of
ASA 75-100 mg/d for 12 months or for 1 month will lead to an increased rate of 12-month
outcomes such as primary patency, limb salvage, freedom from myocardial infarction (MI),
ischemic stroke and survival, in patients receiving endovascular treatment of PAD.
The investigators hypothesize that dual antiplatelet therapy (DAPT) with ASA and clopidogrel
administered for 12 months following iliac, femoropopliteal or below the knee endovascular
intervention will improve primary patency, limb salvage, freedom from ischemic stroke and
survival, in patients with symptomatic PAD.
Clinical endpoints will be analyzed in all subjects who are enrolled, regardless of whether
the trial treatment administered successfully completed for the desired duration. A subject
will be considered enrolled in the trial when he/she is randomized to one of the treatment
arms of the study. All endpoints are subject-based unless otherwise specified.
The primary endpoint is a subject-based 12-month endpoint of the first occurrence of index
limb arterial occlusion, surgical intervention, endovascular intervention, amputation of the
affected limb (primary patency and limb salvage), MI, ischemic stroke or death (survival).
The secondary endpoints are subject-based 12-month endpoints that include: (a) the first
occurrence of any individual component of the primary endpoint, (b) the first occurrence of
the following during follow-up: cardiovascular death, or MI, or ischemic stroke, or any
amputation above the ankle and (c) severe bleeding defined according to the Global
Utilization of Streptokinase and Tissue plasminogen activator for Occluded coronary arteries
(GUSTO) classification. The tertiary endpoint is based on 12-month moderate bleeding
according to the GUSTO classification.
Eligibility
Minimum age: 18 Years.
Maximum age: 90 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
General:
- Signed informed consent
- At least 18 years old
- Documented symptomatic iliac, femoropopliteal (FP) or below-the knee artery (BTK)
atherosclerotic disease (Rutherford/Becker category 2, 3 or ≥4)
- Undergone clinically indicated uncomplicated endovascular intervention to one or more
locations of the iliac, femoropopliteal below-the knee arteries
- Estimated survival ≥1 year in the judgment of the primary operator
- Pre-index procedure use of ASA, clopidogrel or both at any dose
Angiographic:
- De novo or restenotic lesions in the common and/or external iliac artery, superficial
femoral artery (SFA), popliteal artery, tibio-peroneal (TP) trunk, anterior tibial
(AT) artery, peroneal artery (PA) or posterior tibial (PT) artery (applies to all
target lesions if multiple)
- Subjects with multiple planned procedures can be enrolled after the completion of the
last planned procedure.-
Exclusion Criteria:
General:
- Complicated qualifying procedure (perforation, flow limiting dissection, distal
embolization requiring re-intervention, need for repeat endovascular, surgical
revascularization, amputation or blood transfusion prior to hospital discharge
following an index procedure
- Extended hospital stay >7 days following the index procedure
- Allergy to aspirin or clopidogrel
- MI or percutaneous coronary intervention with drug eluting stents within the past 9
months
- Life expectancy less than 12 months due to other medical co-morbid condition(s) that
could limit the subject's ability to participate in the trial, limit the subject's
compliance with the follow-up requirements, or impact the scientific integrity of the
trial
- Known hypersensitivity or contraindication to contrast dye that, in the opinion of
the investigator, cannot be adequately pre-medicated.
- Intolerance to antiplatelet, anticoagulant, or thrombolytic medications
- Platelet count <90,000 mm3 or >600,000 mm3
- Serum creatinine >2. 5 mg/dL
- Dialysis-dependent end stage renal disease
- Pregnancy
- Current participation in another drug or device trial that requires interruption of
dual-antiplatelet therapy with aspirin or clopidogrel for <1y
- Planned surgeries, endovascular or other non-vascular or cardiac procedures
- Concurrent warfarin or other chronic oral anticoagulant therapy
- Contraindication(s) to the use of AT (history of intra-cerebral bleed, presence of
intracerebral mass, recent or <6 weeks gastrointestinal bleed, blood transfusion
within the last 6 weeks, any trauma requiring surgery or blood transfusion within the
last 4 weeks or any surgical procedure within the last 4 weeks.
Angiographic:
- Endovascular intervention to iliac, femoropopliteal or BTK artery bypass graft
- Persistent, intraluminal thrombus of the proposed target lesion at the completion of
the index procedure
- Perforated vessel as evidenced by extravasation of contrast media
- Vascular graft, aneurysm or postsurgical stenosis of the target vessel
Locations and Contacts
Atif Mohammad, MD, Phone: 2147428387, Ext: 76630, Email: Atif.Mohammad@utsouthwestern.edu
University of Texas Southwestern Medical Center, Dallas, Texas 75390, United States; Not yet recruiting Atif Mohammad, MD, Phone: 214-742-8387, Ext: 76630, Email: atif.mohammad@utsouthwestern.edu Preeti Kamath, BDS, MHA, Phone: 2148573048, Email: preeti.kamath@utsouthwestern.edu Subhash Banerjee, MD, Principal Investigator
Additional Information
Related publications: Hirsch AT, Duval S. The global pandemic of peripheral artery disease. Lancet. 2013 Oct 19;382(9901):1312-4. doi: 10.1016/S0140-6736(13)61576-7. Epub 2013 Aug 1. Parikh SV, Saya S, Divanji P, Banerjee S, Selzer F, Abbott JD, Naidu SS, Wilensky RL, Faxon DP, Jacobs AK, Holper EM. Risk of death and myocardial infarction in patients with peripheral arterial disease undergoing percutaneous coronary intervention (from the National Heart, Lung and Blood Institute Dynamic Registry). Am J Cardiol. 2011 Apr 1;107(7):959-64. doi: 10.1016/j.amjcard.2010.11.019. Epub 2011 Jan 20. Diehm C, Schuster A, Allenberg JR, Darius H, Haberl R, Lange S, Pittrow D, von Stritzky B, Tepohl G, Trampisch HJ. High prevalence of peripheral arterial disease and co-morbidity in 6880 primary care patients: cross-sectional study. Atherosclerosis. 2004 Jan;172(1):95-105. Hankey GJ, Norman PE, Eikelboom JW. Medical treatment of peripheral arterial disease. JAMA. 2006 Feb 1;295(5):547-53. Review. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, Hiratzka LF, Murphy WR, Olin JW, Puschett JB, Rosenfield KA, Sacks D, Stanley JC, Taylor LM Jr, White CJ, White J, White RA, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Hunt SA, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B; American Association for Vascular Surgery/Society for Vascular Surgery; Society for Cardiovascular Angiography and Interventions; Society for Vascular Medicine and Biology; Society of Interventional Radiology; ACC/AHA Task Force on Practice Guidelines. ACC/AHA Guidelines for the Management of Patients with Peripheral Arterial Disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Associations for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (writing committee to develop guidelines for the management of patients with peripheral arterial disease)--summary of recommendations. J Vasc Interv Radiol. 2006 Sep;17(9):1383-97; quiz 1398. Banerjee S, Das TS, Abu-Fadel MS, Dippel EJ, Shammas NW, Tran DL, Zankar A, Varghese C, Kelly KC, Weideman RA, Little BB, Reilly RF, Addo T, Brilakis ES. Pilot trial of cryoplasty or conventional balloon post-dilation of nitinol stents for revascularization of peripheral arterial segments: the COBRA trial. J Am Coll Cardiol. 2012 Oct 9;60(15):1352-9. doi: 10.1016/j.jacc.2012.05.042. Epub 2012 Sep 12. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, Hiratzka LF, Murphy WR, Olin JW, Puschett JB, Rosenfield KA, Sacks D, Stanley JC, Taylor LM Jr, White CJ, White J, White RA, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Hunt SA, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B; American Association for Vascular Surgery; Society for Vascular Surgery; Society for Cardiovascular Angiography and Interventions; Society for Vascular Medicine and Biology; Society of Interventional Radiology; ACC/AHA Task Force on Practice Guidelines Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease; American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; Vascular Disease Foundation. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation. 2006 Mar 21;113(11):e463-654. Review.
Starting date: August 2014
Last updated: August 13, 2014
|